Pleural effusion is a common yet clinically significant condition frequently seen in pulmonology and internal medicine. It refers to the accumulation of excess fluid within the pleural space—the thin potential cavity between the visceral and parietal pleura. Normally, this space contains only a small amount of lubricating fluid (about 5–15 mL), which allows the lungs to expand and contract smoothly during breathing. 

When excess fluid collects, lung mechanics are impaired, leading to symptoms such as shortness of breath, cough, and chest pain. Importantly, pleural effusion is not a disease in itself but rather a manifestation of an underlying process, ranging from heart failure and infections to malignancies and trauma. 

Understanding pleural effusion requires knowledge of its types, causes, clinical presentation, diagnostic evaluation, and treatment. This article explores each of these aspects in detail and serves as a reference for healthcare professionals, advanced learners, and informed patients alike. 

Pleural effusion is defined as the abnormal accumulation of fluid within the pleural cavity. Under normal conditions, the balance between fluid entry and lymphatic clearance maintains a thin layer of fluid. Disruption of this equilibrium—by increased production, reduced drainage, or both—leads to effusion. 

Types of Pleural Effusion 

Based on composition: 

• Transudative effusion – due to systemic factors like altered hydrostatic or oncotic pressures (e.g., heart failure, cirrhosis). 

• Exudative effusion – due to local pleural pathology (e.g., infection, malignancy, inflammation). 

Based on appearance: 

• Serous (hydrothorax) – clear, straw-colored fluid. 

• Serosanguinous – fluid mixed with blood. 

• Hemorrhagic (hemothorax) – frank blood in the pleural space. 

• Chylous (chylothorax) – milky lymphatic fluid. 

• Purulent (empyema) – pus caused by infection. 

This classification not only provides diagnostic clues but also guides therapeutic decisions. 

Pleural effusions are common worldwide, with an estimated 1.5 million cases annually in the United States. Their frequency depends on the underlying condition: 

• Heart failure causes over 500,000 cases each year. 

• Parapneumonic effusions complicate 20–40% of bacterial pneumonia cases. 

• Malignant effusions affect about 15% of cancer patients, particularly those with lung and breast cancers. 

The likelihood increases with age and comorbidities such as chronic cardiac, hepatic, and renal diseases, making pleural effusion an important consideration in older and medically complex patients. 

Pleural effusion arises from diverse etiologies that can be grouped into transudative, exudative, and specific types. 

Transudative Causes 

Systemic processes that alter fluid balance: 

• Congestive heart failure (most common cause worldwide) 

• Cirrhosis with hepatic hydrothorax 

• Nephrotic syndrome 

• Hypoalbuminemia (due to malnutrition or protein-losing enteropathy) 

• Constrictive pericarditis 

Exudative Causes 

Local pleural or pulmonary disease: 

• Infections: Pneumonia (parapneumonic effusion, empyema), tuberculosis 

• Malignancies: Lung cancer, breast cancer, lymphomas, metastatic spread 

• Pulmonary embolism 

• Autoimmune disease: Rheumatoid arthritis, systemic lupus erythematosus 

• Pancreatitis or post-cardiac injury (Dressler’s syndrome) 

Other Specific Types 

• Hemothorax: Trauma, ruptured aortic aneurysm, procedural complication 

• Chylothorax: Thoracic duct injury or obstruction, lymphoma 

• Pseudochylothorax: Long-standing effusions from TB or RA with cholesterol buildup 

Identifying the cause is the foundation for appropriate management. 

The pleural space is normally maintained by a balance of fluid filtration and absorption. Disturbances in this balance can occur through: 

1. Increased hydrostatic pressure (e.g., congestive heart failure) 

2. Decreased oncotic pressure (e.g., hypoalbuminemia) 

3. Increased pleural capillary permeability (e.g., infection, malignancy) 

4. Lymphatic obstruction (e.g., tumor infiltration) 

5. Fluid migration from peritoneum (e.g., hepatic hydrothorax) 

6. Direct bleeding (hemothorax) 

7. Leakage of lymphatic fluid (chylothorax) 

Understanding these mechanisms clarifies why effusions are classified as transudates or exudates. 

The presentation of pleural effusion depends on its size, speed of accumulation, and underlying cause. 

Common symptoms include: 

• Shortness of breath (most frequent complaint) 

• Sharp, pleuritic chest pain that worsens with breathing or coughing 

• Non-productive cough 

• Orthopnea in heart failure–related effusions 

Physical examination findings may include: 

• Dullness to percussion over the effusion 

• Reduced or absent breath sounds 

• Decreased tactile fremitus 

• Reduced chest wall expansion on the affected side 

• Tracheal shift (in large effusions) 

• Occasionally, a pleural friction rub 

Symptoms are usually proportional to the effusion’s volume and rate of accumulation. 

Diagnosis requires history, examination, imaging, and fluid analysis. 

Clinical Assessment 

• Past medical history (CHF, liver disease, TB, cancer) 

• Risk factor evaluation 

• Careful physical exam for signs of fluid buildup 

Imaging 

• Chest X-ray: Detects effusions >250 mL; shows blunting of costophrenic angles, meniscus sign. 

• Ultrasound: Highly sensitive, identifies as little as 5–50 mL; also guides thoracentesis. 

• CT scan: Clarifies underlying disease, loculations, and distinguishes pleural thickening. 

Thoracentesis (Fluid Sampling) 

A key diagnostic and therapeutic tool performed under ultrasound guidance. Analysis typically includes: 

• Appearance (clear, purulent, bloody, milky) 

• Protein, LDH, glucose, and pH 

• Cell count and differential 

• Gram stain, culture, cytology (for malignancy) 

• Triglyceride level (for chylothorax) 

Light’s Criteria distinguish transudates from exudates. If one or more are true, the effusion is exudative: 

• Pleural fluid protein/serum protein > 0.5 

• Pleural fluid LDH/serum LDH > 0.6 

• Pleural fluid LDH > 2/3 of normal serum upper limit 

Additional Tests 

• BNP for heart failure–related effusions 

• ADA for tuberculosis 

• Autoimmune markers (ANA, RF) when connective tissue disease is suspected 

Differential Diagnosis of Pleural Effusion 

Conditions that can mimic pleural effusion include: 

• Pulmonary consolidation (e.g., pneumonia) 

• Elevated diaphragm due to subphrenic abscess or hepatomegaly 

• Ascites pushing the diaphragm upward 

• Pleural thickening without actual fluid 

Accurate imaging and clinical correlation are critical to avoid misdiagnosis. 

Treatment aims to relieve symptoms and address the underlying cause. 

General Principles 

• Determine etiology (transudative vs exudative) 

• Assess severity and volume 

• Consider risk of recurrence and complications 

Therapeutic Thoracentesis 

• Provides rapid relief in large or symptomatic effusions 

• Limit fluid removal to <1.5 L at once to reduce re-expansion pulmonary edema risk 

Management by Etiology 

Transudative Effusions 

• Treat heart failure with diuretics and sodium restriction 

• Manage cirrhosis; refractory cases may need TIPS 

• Correct underlying nutritional or renal issues 

Exudative Effusions 

• Parapneumonic effusions: Antibiotics alone if uncomplicated; drainage via chest tube or VATS if complicated or empyema 

• Malignant effusions: Symptomatic relief with thoracentesis, indwelling pleural catheter, or pleurodesis 

• Tuberculous effusions: Standard anti-TB treatment; large effusions may need drainage for comfort 

• Chylothorax: Low-fat diet with medium-chain triglycerides, or surgical duct ligation if persistent 

• Hemothorax: Chest tube drainage; surgical exploration if ongoing bleeding 

Post-Procedure Monitoring 

• Check for pneumothorax after thoracentesis 

• Monitor respiratory function and oxygenation 

Long-Term Care 

• Ongoing management of chronic diseases 

• Palliative strategies for malignant effusions 

• Preventive care to reduce recurrence 

Pleural effusion can cause serious problems if untreated or recurrent. 

Early complications: 

• Respiratory distress 

• Empyema (infected effusion) 

• Sepsis in infectious causes 

• Re-expansion pulmonary edema after drainage 

Late complications: 

• Fibrothorax (scarring leading to restrictive lung disease) 

• Chronic effusions if underlying cause persists 

• Progression of the primary disease (e.g., heart failure, cancer) 

Preventive strategies focus on controlling the underlying conditions: 

• Optimal management of chronic heart, liver, and kidney disease 

• Pneumococcal and influenza vaccination to reduce pneumonia-related effusions 

• Prompt treatment of infections 

• Preventing pulmonary embolism (anticoagulation in high-risk patients) 

• Early TB detection and treatment in endemic areas 

The outlook depends on the cause, timing of treatment, and presence of complications. 

• Effusions from heart failure or pneumonia often resolve with proper treatment. 

• Tuberculous effusions have a good prognosis if treated early. 

• Malignant pleural effusions generally indicate advanced disease and carry a poor prognosis, with survival depending on cancer type. 

Symptom control and quality-of-life improvement remain primary goals in incurable cases. 

Pleural effusion is a frequent clinical finding with diverse causes, ranging from benign systemic disorders to life-threatening malignancies. A structured diagnostic approach—including imaging, thoracentesis, and fluid analysis—helps identify the cause and guide appropriate treatment. 

Management strategies vary, from treating underlying conditions and performing therapeutic thoracentesis to advanced interventions such as chest tube drainage, pleurodesis, or surgery. Preventive care, patient education, and multidisciplinary collaboration are essential to improve outcomes. 

With advancements in imaging, biomarkers, and minimally invasive procedures, pleural effusion care continues to evolve—providing better pathways for both diagnosis and long-term management. 

1. Light RW. Pleural Diseases. 6th ed. Lippincott Williams & Wilkins; 2013. 

2. Porcel JM. Pearls and myths in pleural fluid analysis. Respirology. 2011;16(1):44-52. 

3. Hooper C, Lee YC, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii4-ii17. 

4. American Thoracic Society. Management of Pleural Effusion in Adults. ATS Clinical Practice Guidelines. 2020. 

5. Feller-Kopman D, Light R. Pleural Effusion. N Engl J Med. 2018;378(8):740-751. 

6. Rahman NM, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526.